ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ATRA vs TVGN // ENTERPRISE SCALE & MARKET CAP

Atara Biotherapeutics Inc. (NASDAQ) VS. Tevogen Inc. (NASDAQ) • 15-METRIC TALLY: ATRA 3 — TVGN 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: TVGN
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ATRA VS. TVGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ATRA TVGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 ATRA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -13.02% — TIE /fcf-yield <GO>
Operating Margin 29.70% — — TIE /operating-margins <GO>
Net Profit Margin 27.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) -6.30% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 1/9 +2.00 ATRA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 37.5 37.1 +0.39 ATRA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $85.6M $95.2M -$9.6M TVGN /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ATRA REV TVGN REV ATRA GROSS % TVGN GROSS % ATRA FCF TVGN FCF
FY 2025 $120.8M $0 — — -$50.9M -$12.4M
FY 2024 $128.9M $0 — — -$69.0M -$12.0M
FY 2023 $8.6M $0 — — -$193.0M -$8.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ATRA // BETA —
TVGN // BETA —